Expanding the Immunotherapeutic Toolkit for Late Stage Skin Cancer

Expanding the Immunotherapeutic Toolkit for Late Stage Skin Cancer

Focus on the Rationale and Evidence-Based Role for PD-1 Targeted Immune Checkpoint Inhibition-Defining Unmet Needs in a Challenging Patient Population


Published

Created by

CMEducation Resources symposium

Related Presenters

Darrell Rigel, MS, MD

Darrell Rigel, MS, MD

Program ChairClinical Professor of DermatologyNew York Medical CenterNew York, NY